Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease

Shigeo Horie¹,², Satoru Muto¹,², Haruna Kawano¹,², Tadashi Okada³, Yoshiyuki Shibasaki⁴, Koji Nakajima⁴, Tatsuki Ibuki⁴

Received: 2 June 2020 / Accepted: 2 December 2020 / Published online: 20 January 2021
© The Author(s) 2021

Abstract
Background Tolvaptan slowed the rates of total kidney volume (TKV) growth and renal function decline over a 3-year period in patients with autosomal dominant polycystic kidney disease (ADPKD) enrolled in the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 trial (NCT00428948). In this post hoc analysis of Japanese patients from TEMPO 3:4, we evaluated whether the effects of tolvaptan on TKV and on renal function are interrelated.

Methods One hundred and forty-seven Japanese patients from TEMPO 3:4 were included in this analysis (placebo, n = 55; tolvaptan, n = 92). Tolvaptan-treated patients were stratified into the responder group (n = 37), defined as tolvaptan-treated patients with a net decrease in TKV from baseline to year 3, and the non-responder group (n = 55), defined as tolvaptan-treated patients with a net increase in TKV.

Results Mean changes during follow-up in the placebo, responder, and non-responder groups were 16.99%, −8.33%, and 13.95%, respectively, for TKV and −12.61, −8.47, and −8.58 mL/min/1.73 m², respectively, for estimated glomerular filtration rate (eGFR). Compared with the placebo group, eGFR decline was significantly slowed in both the responder and non-responder groups (P < 0.05).

Conclusion Tolvaptan was effective in slowing eGFR decline, regardless of TKV response, over 3 years in patients with ADPKD in Japan. Treatment with tolvaptan may have beneficial effects on slowing of renal function decline even in patients who have not experienced a reduction in the rate of TKV growth by treatment with tolvaptan.

Keywords Autosomal dominant polycystic kidney disease · Glomerular filtration rate · Japan · Tolvaptan · Total kidney volume

Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disease characterized by age-dependent development of multiple cysts in the kidneys, causing a gradual and irreversible expansion of kidney volume [1]. ADPKD eventually leads to end-stage renal failure and the need for renal replacement therapy in a majority of patients, typically by the fifth or sixth decade of life [2]. Natural history data on the gradual expansion of total kidney volume (TKV) in ADPKD are available, including 8 years of follow-up from the prospective, observational Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) I and II studies [1, 3, 4]. TKV and glomerular filtration rate (GFR) are markers of ADPKD progression, with TKV used...
as a prognostic indicator early in the disease course, prior to significant changes in renal function [4]. Tolvaptan, a vasopressin V2-receptor antagonist, suppresses binding of vasopressin to the V2-receptor in renal epithelial cells, and vasopressin V2-receptor blockade has been shown, in animal models of ADPKD, to inhibit the growth of renal cysts and the decline in renal function [5–9]. In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes (TEMPO) 3:4 clinical trial, a global, multicenter study that included patients from Japan, tolvaptan slowed the rates of TKV growth and renal function decline over a 3-year period compared with placebo in patients with ADPKD [10, 11].

In this post hoc analysis of patients enrolled in TEMPO 3:4 in Japan, we assessed the patterns of TKV response to tolvaptan in ADPKD and explored the factors potentially predictive of TKV response, such as baseline ADPKD risk class [12]. Further, we evaluated possible correlations between the effects of tolvaptan on TKV growth rate and on renal function decline.

Materials and methods

Study design

This study is a post hoc analysis of the Japanese population from TEMPO 3:4, a multicenter, double-blind, placebo-controlled, 3-year clinical study (ClinicalTrials.gov number, NCT00428948) [10, 11]. Patients were enrolled at 129 sites worldwide. Study design, setting, data collection, and enrollment criteria have been previously described in detail [10, 13]. Briefly, eligible patients were aged 18–50 years, with a diagnosis of ADPKD by the Ravine criteria, TKV ≥ 750 mL as measured by magnetic resonance imaging (MRI), and estimated creatinine clearance (Ccr) ≥ 60 mL/min. Patients were randomly assigned in a 2:1 ratio to receive tolvaptan or placebo. Study drug was titrated from a daily split dose of 45/15 mg–60/30 mg and 90/30 mg based on patient-reported tolerability. After the titration phase, patients took the highest dose tolerable for 36 months. The primary endpoint was the annual rate of change in TKV from baseline; secondary endpoints included a composite of time to clinical progression (defined as worsening kidney function, kidney pain, hypertension, and albuminuria) and rate of kidney function decline.

TEMPO 3:4 was conducted in accordance with the ethical principles originating in the Declaration of Helsinki and in compliance with good clinical practice guidelines. The protocol was approved by the institutional review board at each trial site. Written informed consent was obtained from all participants.

Objectives

The objectives of this post hoc analysis were to compare the change in TKV from baseline to year 3 among the placebo, responder, and non-responder groups; identify the factors predictive of decrease in TKV; and explore the correlations between changes in TKV and kidney function.

Patients

Patients who completed the TEMPO 3:4 trial in Japan were stratified into three groups: (1) placebo-treated patients; (2) responders, defined as tolvaptan-treated patients with a net decrease in TKV from baseline to year 3; and (3) non-responders, defined as tolvaptan-treated patients who showed a net increase in TKV.

Evaluations

Data from the end of the tolvaptan titration phase were used for baseline kidney function values. Ccr was calculated by the Cockcroft–Gault formula [14]. Calculation of estimated glomerular filtration rate (eGFR; mL/min/1.73 m2) was performed as follows by two formulae: eGFR by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation modified for Japanese = 0.813 (Japanese coefficient) × 141 × minimum (serum creatinine/κ or 1)α × maximum (serum creatinine/κ or 1) − 1.209 × 0.993Age × 1.018 (if female) × 1.159 (if black) (κ is 0.7 for females and 0.9 for males, α is − 0.329 for females and − 0.411 for males) [15] and eGFR by the Japanese eGFR equation based on serum creatinine (eGFR-J) developed by the Japanese Society of Nephrology = 194 × serum creatinine−1.094 × age−0.287 (if male) and 194 × serum creatinine−1.094 × age−0.287 × 0.739 (if female) [16]. Chronic kidney disease stage was classified based on GFR [17].

Baseline MRI data were assessed in blinded reads to categorize patients into ADPKD risk classes according to prespecified imaging criteria [12]. Patients were categorized as class 1 (typical ADPKD) or class 2 (atypical ADPKD), with class 1 patients further stratified into five subclasses (1A–1E) based on height-adjusted TKV (htTKV) and age. The estimated annual kidney growth rates for each subclass are < 1.5% (1A), 1.5–3.0% (1B), 3.0–4.5% (1C), 4.5–6.0% (1D), and > 6.0% (1E), with a theoretical initial htTKV of 150 mL/m. In the analysis of predictive factors for change in TKV, ADPKD risk class was expressed on an ordinal scale from class 1B to 1E.

Statistical analysis

The proportions of patients with a net decrease in TKV from baseline to year 3 in the placebo and tolvaptan groups
were compared by the chi-square test. Factors affecting decrease in TKV were analyzed by univariate logistic regression, with calculation of odds ratio (OR), 95% confidence interval (CI), and P values. The covariates analyzed included demographic characteristics, stratification factors, medical history, current medication, polycystic kidney disease characteristics, and kidney function parameters. Factors found to be significant were further analyzed in a multiple logistic regression model.

To evaluate the correlations between changes in TKV and changes in kidney function parameters from baseline to year 3, Pearson’s correlation coefficient (r), simple regression analysis parameter estimate, standard error, 95% CI, and P value were calculated. Changes in TKV, kidney function, and urine osmolality from baseline to year 3 were compared among the placebo and tolvaptan groups using Tukey–Kramer’s honestly significant difference test.

Statistical significance was defined as P < 0.05. All statistical analyses were performed using SAS 9.4 and JMP 13 (SAS Institute, Cary, North Carolina).

## Results

### Patient characteristics

One hundred and forty-seven Japanese patients from the TEMPO 3:4 trial were included in this analysis (placebo, n = 55; tolvaptan, n = 92). By ADPKD risk classification, 9.5% of patients were class 1B, 40.8% class 1C, 30.6% class 1D, and 16.3% class 1E. Tolvaptan-treated patients were stratified into responders (n = 37), defined as patients who achieved a net decrease in TKV from baseline to year 3, or non-responders (n = 55), defined as patients who experienced a net increase in TKV from baseline to year 3 (Fig. 1). Patient characteristics and demographic data in the placebo, responder, and non-responder groups are shown in Table 1. The distribution of patients in each risk subclass was similar between the placebo and tolvaptan groups (Fig. 2). Overall, 40.2% (37/92) of tolvaptan-treated patients, compared with 5.5% (3/55) of placebo-treated patients, experienced a net decrease in TKV from baseline to year 3 (P < 0.0001). Tolvaptan was associated with decreased TKV in 60% of
### Table 1  Patient characteristics and demographic data

| Demographic characteristic | Placebo (n = 55) | Tolvaptan (n = 92) |
|----------------------------|----------------|-----------------|
| Sex (male)                 | 33 (60.0) | 12 (32.4) | 36 (65.5) |
| Age (years)                | 40.5 ± 5.6 | 39.7 ± 5.4 | 38.1 ± 6.5 |
| Height (cm)                | 169.5 ± 6.9 | 164.0 ± 8.8 | 169.3 ± 8.2 |
| Weight (kg)                | 66.4 ± 13.1 | 61.2 ± 12.5 | 69.2 ± 12.2 |
| BMI (kg/m²)                | 23.0 ± 3.4 | 22.6 ± 2.9 | 24.0 ± 3.3 |

| Polycystic kidney disease characteristic | Placebo group (n = 55) | Responders group (n = 37) | Non-responders group (n = 55) |
|-----------------------------------------|------------------------|---------------------------|-----------------------------|
| Systolic blood pressure (mm Hg)        | 125.4 ± 12.8           | 123.2 ± 12.2              | 127.4 ± 14.6                |
| Diastolic blood pressure (mm Hg)       | 80.8 ± 9.8             | 79.5 ± 11.3               | 81.9 ± 14.1                 |
| Mean blood pressure (mm Hg)            | 95.7 ± 10.0            | 94.1 ± 11.0               | 97.0 ± 13.2                 |
| TKV (mL)                                | 1582.2 ± 643.8         | 1434.3 ± 640.6            | 1518.9 ± 559.8              |
| Height-adjusted TKV (mL/m)             | 928.5 ± 362.1          | 871.7 ± 377.9             | 897.7 ± 327.3               |
| Cr (mg/dL)                              | 0.97 ± 0.27            | 0.95 ± 0.32               | 1.03 ± 0.32                 |
| i/Cr [(mg/mL)⁻¹]                       | 111.7 ± 33.7           | 115.7 ± 34.4              | 106.4 ± 32.4                |
| Ccr (mL/min)                            | 93.1 ± 23.1            | 84.3 ± 21.8               | 95.1 ± 27.0                 |
| eGFR CKD-EPI (mL/min/1.73 m²)³         | 73.7 ± 16.4            | 71.3 ± 17.2               | 72.0 ± 17.7                 |
| eGFR-J (mL/min/1.73 m²)²                | 66.3 ± 17.1            | 63.6 ± 16.5               | 65.0 ± 17.0                 |
| Urine albumin-to-creatinine ratio       | 10.7 ± 18.3            | 7.5 ± 7.8                 | 11.2 ± 16.5                 |
| CysC (mg/L)                             | 0.77 ± 0.19            | 0.76 ± 0.20               | 0.80 ± 0.20                 |
| Urine osmolality (mOsm/kg)             | 475.0 ± 137.1          | 440.8 ± 140.6             | 465.7 ± 151.2               |

| CKD stageabetic                         |                        |                            |                            |
| G1                                      | 3 (5.5)                | 2 (5.4)                    | 5 (9.3)                    |
| G2                                      | 31 (56.4)              | 20 (54.1)                  | 25 (46.3)                  |
| G3a                                     | 17 (30.9)              | 8 (21.6)                   | 18 (33.3)                  |
| G3b                                     | 4 (7.3)                | 7 (18.9)                   | 6 (11.1)                   |
| G4                                      | 0 (0.0)                | 0 (0.0)                    | 0 (0.0)                    |
| G5                                      | 0 (0.0)                | 0 (0.0)                    | 0 (0.0)                    |

| ADPKD risk classification⁵              |                        |                            |                            |
| 1A                                      | 0 (0.0)                | 0 (0.0)                    | 0 (0.0)                    |
| 1B                                      | 4 (7.3)                | 6 (16.2)                   | 4 (7.3)                    |
| 1C                                      | 26 (47.3)              | 13 (35.1)                  | 21 (38.2)                  |
| 1D                                      | 17 (30.9)              | 11 (29.7)                  | 17 (30.9)                  |
| 1E                                      | 8 (14.5)               | 3 (8.1)                    | 13 (23.6)                  |
| 2A/2B                                   | 0 (0.0)                | 4 (10.8)                   | 0 (0.0)                    |

| Medical history                         |                        |                            |                            |
| Hematuria                                | 16 (29.1)              | 7 (18.9)                   | 12 (21.8)                  |
| Kidney pain                              | 4 (7.3)                | 4 (10.8)                   | 6 (10.9)                   |
| Nephrolithiasis                         | 7 (12.7)               | 2 (5.4)                    | 6 (10.9)                   |
| Urinary tract infection                  | 3 (5.5)                | 4 (10.8)                   | 4 (7.3)                    |
| Anemia                                   | 3 (5.5)                | 4 (10.8)                   | 5 (9.1)                    |
| Proteinuria                              | 20 (36.4)              | 12 (32.4)                  | 14 (25.5)                  |

| Current medication                       |                        |                            |                            |
| ACE inhibitor                            | 8 (14.5)               | 2 (5.4)                    | 3 (5.5)                    |
| ARB                                      | 36 (65.5)              | 17 (45.9)                  | 36 (65.5)                  |
| ACE inhibitor, ARB, or both              | 38 (69.1)              | 18 (48.6)                  | 37 (67.3)                  |
| Beta-blocker                             | 7 (12.7)               | 2 (5.4)                    | 7 (12.7)                   |
| Calcium channel blocker                  | 23 (41.8)              | 7 (18.9)                   | 21 (38.2)                  |
| Diuretic                                 | 2 (3.6)                | 0 (0.0)                    | 2 (3.6)                    |
class 1B patients (6 responders among 10 tolvaptan-treated patients), 38.2% of class 1C patients (13 responders among 34 tolvaptan-treated patients), 39.3% of class 1D patients (11 responders among 28 tolvaptan-treated patients), and 18.8% of class 1E patients (3 responders among 16 tolvaptan-treated patients). Calcium channel blockers were prescribed in significantly fewer patients in the responder group than in either the placebo ($P = 0.0216$) or the non-responder ($P = 0.0490$) group.

**Change in TKV**

The time course of percent change in TKV at each visit is shown in Fig. 3 for each group. Changes in TKV from baseline to each year of follow-up were significantly different between the placebo and responder groups ($P < 0.0001$) and between the responder and non-responder groups ($P < 0.0001$). No statistically significant differences between the placebo and non-responder groups were observed. In the responder group, TKV was decreased in all patients at 12 months, with the decreases maintained throughout 3 years of treatment in all patients, with the exception of one patient at year 2 (Fig. 4).

**Predictors of TKV decrease**

The significant predictive factors for TKV decrease with tolvaptan were sex (OR for males 0.25; 95% CI 0.10–0.61; $P = 0.0024$), height (OR 0.93; 95% CI 0.88–0.98; $P = 0.0063$), weight (OR 0.95; 95% CI 0.91–0.98; $P = 0.0050$), and body mass index (BMI; OR 0.85; 95% CI 0.73–0.99; $P = 0.0333$) (Table 2). Multiple logistic regression analysis was performed using two factors, sex and BMI. Sex was a significant predictor of TKV response (OR for male sex 0.31; 95% CI 0.12–0.81; $P = 0.0165$) (Table 3).

**Change in kidney function**

Changes in eGFR (mean ± standard deviation [SD]) from baseline to year 3 in the placebo, responder, and non-responder groups were $-14.55 ± 8.26$, $-9.13 ± 5.77$, and $-9.31 ± 9.52$ mL/min/1.73 m², respectively, by the CKD-EPI equation and $-12.61 ± 7.23$, $-8.47 ± 5.03$, and $-8.58 ± 8.93$ mL/min/1.73 m², respectively, by the eGFR-J equation (Table 4).

Compared with the placebo group, the decline in eGFR assessed by the CKD-EPI ($P = 0.0066$, $P = 0.0032$) and eGFR-J ($P = 0.0269$, $P = 0.0152$) equations was significantly suppressed in both the responder and non-responder groups (Fig. 5). No statistically significant difference between the responder and non-responder groups was observed for any biomarker of renal function (eGFR CKD-EPI, eGFR-J, serum creatinine [Cr], reciprocal of serum creatinine [1/Cr], cystatin C [CysC], and Ccr) (Table 4). Changes in Ccr (mean ± SD) from baseline to year 3 in the placebo, responder, and non-responder groups were $-16.67 ± 11.31$, $-10.81 ± 9.23$, and $-10.65 ± 13.73$ mL/min, respectively.

Data from additional analyses for changes in eGFR in class 1 patients and by age are summarized in Online Resources 1 and 2.

**Associations between TKV and renal function**

In the placebo group, changes in Cr ($r = 0.5971$; $P < 0.0001$) and CysC ($r = 0.5240$; $P < 0.0001$) from baseline to year 3 demonstrated a significant positive correlation with TKV, while Ccr ($r = -0.3110$; $P = 0.0490$) (Table 5). However, no statistically significant associations between changes in TKV and renal function were observed in either the responder or the non-responder group.
Urine osmolality

We examined changes in urine osmolality during the trial. Mean ± SD urine osmolalities in the placebo, responder, and non-responder groups were 475.0 ± 137.1, 440.8 ± 140.6, and 465.7 ± 151.2 mOsm/kg, respectively, at baseline and 413.4 ± 132.5, 250.4 ± 114.6, and 247.7 ± 137.1 mOsm/kg, respectively, at month 36. Mean urine osmolality decreased significantly more in the tolvaptan-treated groups compared with the placebo group, but there were no differences between the responder group and the non-responder group at 12, 24, and 36 months (Table 6).

Fig. 2 Risk classification by hTKV and age in class 1 patients. Vertical scale is a log₂ scale. Plots are baseline values of hTKV and age. Class 1 was stratified into five subclasses (1A–1E) based on estimated kidney growth rates: yearly rates of increase of <1.5% (1A), 1.5–3.0% (1B), 3.0–4.5% (1C), 4.5–6.0% (1D), and >6.0% (1E), with a theoretical initial hTKV of 150 mL/m. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3. hTKV height-adjusted total kidney volume, TKV total kidney volume.
Discussion

Mechanisms of cyst expansion in ADPKD and the associated increase in TKV are based on reduced intracellular Ca\textsuperscript{2+} influx caused by mutations in either \textit{PKD1} or \textit{PKD2}, increased cellular adenosine 3', 5'-cyclic monophosphate (cAMP) levels, and aberrant Ras/Raf/ERK activation \cite{18}. Tolvaptan blocks the vasopressin V\textsubscript{2}-receptor, reducing cAMP levels \cite{18}. The progression of ADPKD is characterized by a continuous expansion of cyst volume, a process that was well represented by change in TKV over time in the placebo group of this study (Fig. 3). During longitudinal follow-up in CRISP II, htTKV and GFR exhibited

![Graph showing time course of change in TKV over 3 years in the placebo, responder, and non-responder groups. Values are expressed as mean and standard deviation. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3. \( P < 0.0001 \) based on Tukey–Kramer’s honestly significant difference test comparing percent change in TKV from baseline to each year of follow-up between the placebo and responder groups (*) and between the responder and non-responder groups (†). TKV total kidney volume.]

![Graph showing time course of TKV in each patient throughout the treatment period. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3. TKV total kidney volume.]

![Graph showing time course of TKV over 3 years in the placebo, responder, and non-responder groups. Values are expressed as mean and standard deviation. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3. TKV total kidney volume.]

![Graph showing time course of TKV in each patient throughout the treatment period. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3. TKV total kidney volume.]

![Graph showing time course of TKV in each patient throughout the treatment period. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3. TKV total kidney volume.]

![Graph showing time course of TKV in each patient throughout the treatment period. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3. TKV total kidney volume.]
Table 2 Univariate analysis of factors predictive of TKV reduction

| Demographic characteristic | Odds ratio | 95% CI | P value |
|-----------------------------|------------|--------|---------|
| Sex (male)                  | 0.25       | 0.10–0.61 | 0.0024 |
| Age (years)                 | 1.05       | 0.97–1.12 | 0.2093 |
| Height (cm)                 | 0.93       | 0.88–0.98 | 0.0063 |
| Weight (kg)                 | 0.95       | 0.91–0.98 | 0.0050 |
| BMI (kg/m²)                 | 0.85       | 0.73–0.99 | 0.0333 |

| Stratification factor       | Odds ratio | 95% CI | P value |
|-----------------------------|------------|--------|---------|
| Hypertension                | 0.51       | 0.20–1.26 | 0.1453 |
| Ccr < 80 mL/min             | 2.36       | 1.00–5.59 | 0.0509 |
| TKV < 1500 mL               | 1.69       | 0.64–4.45 | 0.2859 |

| Medical history             | Odds ratio | 95% CI | P value |
|-----------------------------|------------|--------|---------|
| Hematuria                   | 0.84       | 0.29–2.37 | 0.7364 |
| Kidney pain                 | 0.99       | 0.26–3.78 | 0.9882 |
| Nephrolithiasis             | 0.47       | 0.09–2.45 | 0.3676 |
| Urinary tract infection     | 1.55       | 0.36–6.61 | 0.5572 |
| Anemia                      | 1.21       | 0.30–4.85 | 0.7856 |
| Proteinuria                 | 1.41       | 0.56–3.52 | 0.4670 |

| Current medication          | Odds ratio | 95% CI | P value |
|-----------------------------|------------|--------|---------|
| ACE inhibitor               | 0.99       | 0.16–6.24 | 0.9919 |
| ARB                         | 0.45       | 0.19–1.05 | 0.0654 |
| ACE inhibitor, ARB, or both | 0.46       | 0.20–1.08 | 0.0762 |
| Beta-blocker                | 0.39       | 0.08–2.00 | 0.2601 |
| Calcium channel blocker     | 0.38       | 0.14–1.01 | 0.0531 |
| Diuretic                    | N.A        |        |         |

| Polycystic kidney disease characteristic | Odds ratio | 95% CI | P value |
|-----------------------------------------|------------|--------|---------|
| ADPKD risk classification               | 0.63       | 0.38–1.03 | 0.0663 |
| Systolic blood pressure (mm Hg)         | 0.98       | 0.95–1.01 | 0.1622 |
| Diastolic blood pressure (mm Hg)        | 0.99       | 0.95–1.02 | 0.3975 |
| Mean blood pressure (mm Hg)             | 0.98       | 0.95–1.02 | 0.2665 |
| TKV (mL)                                 | 1.00       | 1.00–1.00 | 0.5003 |
| Height-adjusted TKV (mL/m)              | 1.00       | 1.00–1.00 | 0.7230 |
| Urine albumin-to-creatinine ratio       | 0.97       | 0.93–1.02 | 0.2589 |

| Kidney function                        | Odds ratio | 95% CI | P value |
|----------------------------------------|------------|--------|---------|
| Cr (mg/dL)                              | 0.44       | 0.11–1.78 | 0.2514 |
| CysC (mg/L)                             | 0.31       | 0.04–2.73 | 0.2947 |
| Urine osmolality (mOsm/kg)              | 1.00       | 1.00–1.00 | 0.4285 |
| f(Cr) (mg/mL)−1                        | 1.01       | 1.00–1.02 | 0.1897 |
| Ccr (mL/min)                            | 0.98       | 0.96–1.00 | 0.0503 |
| eGFR CKD-EPI (mL/min/1.73 m²)           | 1.00       | 0.97–1.02 | 0.8468 |
| eGFR-J (mL/min/1.73 m²)                 | 0.99       | 0.97–1.02 | 0.6873 |

Factors were analyzed by logistic regression

I/Cr reciprocal of serum creatinine, ACE angiotensin-converting enzyme, ADPKD autosomal dominant polycystic kidney disease, ARB angiotensin II receptor blocker, BMI body mass index, Ccr estimated creatinine clearance, CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, Cr serum creatinine, CysC serum cystatin C, eGFR estimated glomerular filtration rate, eGFR-J estimated glomerular filtration rate by the Japanese equation based on serum creatinine, N.A. not available, TKV total kidney volume

ADPKD risk classification was defined on an ordinal scale from class 1B to 1E

Table 3 Multivariate analysis of factors predictive of TKV reduction

| Factor                        | Odds ratio | 95% CI | P value |
|-------------------------------|------------|--------|---------|
| Sex (male)                    | 0.31       | 0.12–0.81 | 0.0165 |
| BMI (kg/m²)                   | 0.92       | 0.78–1.08 | 0.2984 |

Factors were analyzed by logistic regression

BMI body mass index, CI confidence interval, TKV total kidney volume

aADPKD risk classification was defined on an ordinal scale from class 1B to 1E

bCcr calculated by the Cockcroft–Gault formula

ceGFR calculated by the CKD-EPI equation modified for Japanese

A significant negative correlation has also been observed in a Japanese cohort, in which a significant negative correlation between baseline TKV and eGFR slope was observed [19]. Thus, TKV is used as a surrogate biomarker of ADPKD progression [1].

In our study, female sex was a significant positive predictor of tolvaptan’s effect in reducing TKV growth. Since there was no modification of tolvaptan dosage for either sex in this study, it is possible that the same dosage may have produced higher serum drug concentrations in females. However, pharmacokinetic analyses in patients with ADPKD have shown that there are no sex differences in the blood concentration of tolvaptan [20]; therefore, we could not define why female sex was identified as a predictor.

In a previous post hoc analysis of TEMPO 3:4, it was reported that baseline urine osmolality influenced disease progression and the response to tolvaptan in patients with ADPKD [21]. The importance of vasopressin is further supported by recent findings on copeptin levels, a surrogate marker for arginine vasopressin (AVP). Copeptin concentrations are higher in men, positively correlate with TKV growth, and predict response to tolvaptan in ADPKD [22, 23]. Subsequent research has confirmed that men have a consistently higher urine osmolality than women [24]. In the present analysis, however, urine osmolality did not predict the effect of tolvaptan in reducing TKV growth. Additionally, there were no differences in urine osmolality at years 1, 2, and 3 between the responder and non-responder groups.

In our study, female sex was a significant positive predictor of tolvaptan’s effect in reducing TKV growth. Since there was no modification of tolvaptan dosage for either sex in this study, it is possible that the same dosage may have produced higher serum drug concentrations in females. However, pharmacokinetic analyses in patients with ADPKD have shown that there are no sex differences in the blood concentration of tolvaptan [20]; therefore, we could not define why female sex was identified as a predictor.

In a previous post hoc analysis of TEMPO 3:4, it was reported that baseline urine osmolality influenced disease progression and the response to tolvaptan in patients with ADPKD [21]. The importance of vasopressin is further supported by recent findings on copeptin levels, a surrogate marker for arginine vasopressin (AVP). Copeptin concentrations are higher in men, positively correlate with TKV growth, and predict response to tolvaptan in ADPKD [22, 23]. Subsequent research has confirmed that men have a consistently higher urine osmolality than women [24]. In the present analysis, however, urine osmolality did not predict the effect of tolvaptan in reducing TKV growth. Additionally, there were no differences in urine osmolality at years 1, 2, and 3 between the responder and non-responder groups.

ADPKD risk classification is a practical method for evaluating the prognosis of patients with ADPKD [12, 25, 26]. In the model developed by Irazabal and colleagues, rates of TKV growth and eGFR decline increase stepwise from class 1A to 1E in ADPKD with a typical presentation. We assessed if there was any difference in risk class distribution between Japanese patients and the global population. In our analysis, classes 1B, 1C, 1D, and 1E constituted 9.5%, 40.8%, 30.6%, and 16.3%, respectively, of the total 147 patients (Table 1), which is a similar distribution to that
in the TEMPO 3:4 global population (7.6%, 38.2%, 35.4%, 18.8% for classes 1B, 1C, 1D, and 1E, respectively) [25]. Taken together, our findings indicate no reason to suggest that the effects of tolvaptan in slowing renal function decline are dependent on changes in TKV growth rate. However, the non-responder group included more class 1E patients compared with the responder group (8.1% vs 23.6%). We cannot deny the possibility that TKV growth in the non-responder group might have been much faster and masked the efficacy of tolvaptan.

Table 4  Changes in kidney function from baseline to year 3

| Kidney function parameter | Group                      | Placebo (n = 55) | Responders (n = 37) | Non-responders (n = 54) | P value |
|---------------------------|----------------------------|------------------|---------------------|------------------------|---------|
|                           |                            | PL vs R          | PL vs NR            | R vs NR                |         |
| Cr (mg/dL)                | 0.28 ± 0.38                | 0.15 ± 0.16      | 0.17 ± 0.27         | 0.0853                 | 0.1221  | 0.9311  |
| CysC (mg/L)               | 0.20 ± 0.23                | 0.10 ± 0.11      | 0.14 ± 0.17         | 0.0297                 | 0.2236  | 0.5334  |
| 1/Cr [(mg/mL)−¹]          | −17.90 ± 12.57             | −12.12 ± 8.84    | −11.47 ± 14.35      | 0.0785                 | 0.0217  | 0.9674  |
| Ccr (mL/min)              | −16.67 ± 11.31             | −10.81 ± 9.23    | −10.65 ± 13.73      | 0.0548                 | 0.0237  | 0.9978  |
| eGFR CKD-EPI (mL/min/1.73 m²) | −14.55 ± 8.26             | −9.13 ± 5.77     | −9.31 ± 9.52        | 0.0066                 | 0.0032  | 0.9943  |
| eGFR-J (mL/min/1.73 m²)     | −12.61 ± 7.23              | −8.47 ± 5.03     | −8.58 ± 8.93        | 0.0269                 | 0.0152  | 0.9970  |

Data are mean ± standard deviation. P values based on Tukey–Kramer’s honestly significant difference test are shown. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3.

I/Cr reciprocal of serum creatinine, Ccr estimated creatinine clearance, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, Cr serum creatinine, CysC serum cystatin C, eGFR estimated glomerular filtration rate, eGFR-J estimated glomerular filtration rate by the Japanese equation based on serum creatinine, NR non-responder, PL placebo, R responder, TKV total kidney volume

Table 4

- Cr (mg/dL): Placebo, 0.28 ± 0.38; Responders, 0.15 ± 0.16; Non-responders, 0.17 ± 0.27.
- CysC (mg/L): Placebo, 0.20 ± 0.23; Responders, 0.10 ± 0.11; Non-responders, 0.14 ± 0.17.
- 1/Cr [(mg/mL)−¹]: Placebo, −17.90 ± 12.57; Responders, −12.12 ± 8.84; Non-responders, −11.47 ± 14.35.
- Ccr (mL/min): Placebo, −16.67 ± 11.31; Responders, −10.81 ± 9.23; Non-responders, −10.65 ± 13.73.
- eGFR CKD-EPI (mL/min/1.73 m²): Placebo, −14.55 ± 8.26; Responders, −9.13 ± 5.77; Non-responders, −9.31 ± 9.52.
- eGFR-J (mL/min/1.73 m²): Placebo, −12.61 ± 7.23; Responders, −8.47 ± 5.03; Non-responders, −8.58 ± 8.93.

Fig. 5  Change in eGFR from baseline to year 3. Values are expressed as mean and standard deviation. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3. *P < 0.05 and **P < 0.01 based on Tukey–Kramer’s honestly significant difference test comparing change in eGFR from baseline to year 3 between the placebo and responder groups or between the placebo and non-responder groups. CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, eGFR estimated glomerular filtration rate, eGFR Japanese estimated glomerular filtration rate by the Japanese equation based on serum creatinine, TKV total kidney volume.
Table 5 Correlations between changes in TKV and kidney function

| Group       | Kidney function parameter | n   | Mean     | SD    | Univariate correlation coefficient | Univariate regression analysis | P value |
|-------------|---------------------------|-----|----------|-------|-----------------------------------|-------------------------------|---------|
|             |                           |     |          |       |                                   |                               |         |
|             |                           |     |          |       | Estimate | SE   | 95% CI |       |
|             |                           |     |          |       |          |      |        |       |
| Placebo     | Cr (mg/dL)                | 55  | 0.28     | 0.38  | 0.5971   | 28.02 | 5.17   | 17.65 to 38.39 | <0.0001 |
|             | CysC (mg/L)               | 55  | 0.20     | 0.23  | 0.5240   | 40.72 | 9.09   | 22.49 to 58.96 | <0.0001 |
|             | 1/Cr [(mg/mL)^-1]         | 55  | -17.90   | 12.57 | -0.1518  | -0.21 | 0.19   | -0.60 to 0.17 | 0.2687 |
|             | Ccr (mL/min)^b            | 55  | -16.67   | 11.31 | -0.3110  | -0.48 | 0.20   | -0.89 to -0.08 | 0.0208 |
|             | eGFR CKD-EPI (mL/min/1.73 m^2)^c | 55 | -14.55 | 8.26  | -0.2811  | -0.60 | 0.28   | -1.17 to -0.04 | 0.0376 |
|             | eGFR-J (mL/min/1.73 m^2)^d | 55  | -12.61   | 7.23  | -0.2333  | -0.57 | 0.33   | -1.22 to 0.08 | 0.0865 |
| Responders  | Cr (mg/dL)                | 37  | 0.15     | 0.16  | 0.3232   | 10.48 | 5.18   | -0.05 to 21.00 | 0.0510 |
|             | CysC (mg/L)               | 37  | 0.10     | 0.11  | 0.1922   | 9.13  | 7.88   | -6.86 to 25.11 | 0.2544 |
|             | 1/Cr [(mg/mL)^-1]         | 37  | -12.12   | 8.84  | -0.1750  | -0.10 | 0.10   | -0.29 to 0.09 | 0.3001 |
|             | Ccr (mL/min)^b            | 37  | -10.81   | 9.23  | -0.2161  | -0.12 | 0.09   | -0.30 to 0.17 | 0.1988 |
|             | eGFR CKD-EPI (mL/min/1.73 m^2)^c | 37 | -9.13   | 5.77  | -0.2967  | -0.26 | 0.14   | -0.55 to 0.03 | 0.0746 |
|             | eGFR-J (mL/min/1.73 m^2)^d | 37  | -8.47    | 5.03  | -0.1661  | -0.17 | 0.17   | -0.51 to 0.17 | 0.3258 |
| Non-responders | Cr (mg/dL)             | 54  | 0.17     | 0.27  | 0.1856   | 8.28  | 6.08   | -3.92 to 20.48 | 0.1791 |
|             | CysC (mg/L)               | 54  | 0.14     | 0.17  | 0.1764   | 12.46 | 9.64   | 6.88 to 31.81 | 0.2019 |
|             | 1/Cr [(mg/mL)^-1]         | 54  | -11.47   | 14.35 | -0.1788  | -0.15 | 0.11   | -0.37 to 0.08 | 0.1959 |
|             | Ccr (mL/min)^b            | 54  | -10.65   | 13.73 | -0.1139  | -0.10 | 0.12   | -0.34 to 0.14 | 0.4124 |
|             | eGFR CKD-EPI (mL/min/1.73 m^2)^c | 54 | -9.31   | 9.52  | -0.2302  | -0.29 | 0.17   | -0.62 to 0.05 | 0.0940 |
|             | eGFR-J (mL/min/1.73 m^2)^d | 54  | -8.58    | 8.93  | -0.2043  | -0.27 | 0.18   | -0.63 to 0.09 | 0.1384 |

Mean and SD represent changes in kidney function parameters from baseline to year 3. Correlation coefficient, estimate, SE, 95% CI, and P value show correlations between changes in TKV and kidney function parameters from baseline to year 3. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3.

1/Cr reciprocal of serum creatinine, Ccr estimated creatinine clearance, CI confidence interval, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, Cr serum creatinine, CysC serum cystatin C, eGFR estimated glomerular filtration rate, eGFR-J estimated glomerular filtration rate by the Japanese equation based on serum creatinine, SD standard deviation, SE standard error, TKV total kidney volume

aPearson’s correlation coefficient

bCcr calculated by the Cockcroft–Gault formula
cCKD-EPI CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, Cr serum creatinine, CysC serum cystatin C, eGFR estimated glomerular filtration rate, eGFR-J estimated glomerular filtration rate by the Japanese equation based on serum creatinine, SD standard deviation, SE standard error, TKV total kidney volume

deGFR calculated by the CKD-EPI equation modified for Japanese

eGFR calculated by the Japanese eGFR equation based on Cr, as developed by the Japanese Society of Nephrology

Table 6 Changes in urine osmolality from baseline to year 3

| Urine osmolality (mOsm/kg) | Group               | Placebo               | Responders            | Non-responders        | P value |
|---------------------------|---------------------|-----------------------|-----------------------|-----------------------|---------|
|                           |                     |                       |                       |                       |         |
|                           |                     | n=53                  | n=36                  | n=55                  |         |
| Baseline                  | 475.0 ± 137.1       | 440.8 ± 140.6         | 465.7 ± 151.2         | 0.5149                | 0.9398  | 0.6937 |
| Month 12                  | 401.2 ± 160.3       | 214.7 ± 99.5          | 249.7 ± 140.9         | <0.0001               | <0.0001 | 0.4830 |
| Month 24                  | 420.1 ± 160.0       | 239.4 ± 103.6         | 234.8 ± 108.3         | <0.0001               | <0.0001 | 0.9854 |
| Month 36                  | 413.4 ± 132.5       | 250.4 ± 114.6         | 247.7 ± 137.1         | <0.0001               | <0.0001 | 0.9949 |

Data are mean ± standard deviation. P values based on Tukey–Kramer’s honestly significant difference test are shown. Responders: tolvaptan-treated patients with a net decrease in TKV from baseline to year 3. Non-responders: tolvaptan-treated patients with a net increase in TKV from baseline to year 3.

NR non-responder, PL placebo, R responder, TKV total kidney volume
Several lines of evidence suggest that vasopressin contributes to non-diabetic and diabetic chronic kidney disease progression. Plasma vasopressin levels are increased in animal models and in patients with non-diabetic chronic kidney disease, in animal models of streptozotocin-induced and genetic diabetes mellitus, and in patients with type I and type II diabetes mellitus [27, 28]. Plasma levels of copeptin are inversely correlated with GFR [29]. Previous studies have shown that AVP is associated with the progression of chronic kidney disease. Plasma copeptin levels are associated with a decline in kidney function in recipients of kidney transplant [30], and high plasma copeptin levels are associated with lower GFR in patients with type II diabetes mellitus [31]. Furthermore, treatment with AVP V1a and V2 receptor antagonists has been shown to cause a significant reduction in blood pressure, proteinuria, and glomerulosclerosis in animal models with 5/6 nephrectomy [32]. Although the underlying mechanisms are unknown, inhibiting the AVP V2-receptor may confer a renal protective effect, independent of the kidney volume reduction. Thus, tolvaptan might plausibly be beneficial for patients with ADPKD in whom there is little treatment effect on TKV.

Limitations of this study are its small size and use of a sample from a single ethnic group. Potential differences in genetic features between responders and non-responders warrant further investigation.

Currently, in Japan and other countries, the labeling for tolvaptan in ADPKD stresses its effect on reducing the rate of TKV increase. In the United States, following the Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trial [33], which did not assess changes in TKV, the Food and Drug Administration approved tolvaptan with an indication to slow renal function decline. In our analysis of the Japanese cohort of TEMPO 3:4, we have shown that tolvaptan suppressed eGFR decline regardless of the effects on TKV growth. Accordingly, we propose that patients receiving treatment with tolvaptan who do not experience a reduction in the rate of TKV growth should not discontinue treatment as there may still be beneficial effects on slowing of renal function decline.

Acknowledgements The authors thank all the patients, investigators, and staff at the participating sites for their support to the study. The authors also thank the following investigators who participated in the TEMPO 3:4 trial: Sekiya Shibazaki, Toshio Mochizuki, Saori Nishio (Hokkaido University Hospital), Sadayoshi Ito (Tohoku University Hospital), Koichi Asahi, Tsuyoshi Watanabe, Tetsuo Kato (Fukushima Medical University Hospital), Eiji Kusano (Jichi Medical School Hospital), Michio Kuwahara, Yusuke Tsukamoto (Shiga General Hospital), Hajime Hasegawa (Saitama Medical Center), Koichi Kamura (National Hospital Organization Chiba-East Hospital), Naoki Nihei, Yukio Naya (Chiba University Hospital), Kosaku Nitta (Tokyo Women’s Medical University Hospital), Yasuhiro Iino (Nippon Medical School Hospital), Sei Sasaki (Tokyo Medical and Dental University Hospital Faculty of Medicine), Kenmei Takaichi (Toranomon Hospital), Tatsuo Hosoya (The Jikei University Hospital), Kikuo Nutahara (Kyorin University Hospital), Koju Kamata, Kazunari Yoshida (Kitasato University Hospital), Masayuki Endoh (Tokai University Hospital), Yoshifumi Ubara (Toranomon Hospital Kagijaya), Ichiei Narita (Niigata University Medical and Dental Hospital), Yoshihide Fujigaki (Hamamatsu University School of Medicine, University Hospital), Yukio Yuzawa, Satoshi Sugiyama, Yoshishiki Hiki, Midori Hasegawa (Fujita Health University Hospital), Noriyuki Iehara, Atsushi Fukatsu (Kyoto University Hospital), Koichi Seta, Akira Sugawara (National Hospital Organization Kyoto Medical Center), Eiji Ishimura (Osaka City University Hospital), Mikio Okamura (Ohno Memorial Hospital), Yoshitaka Isaka, Eiya Imai (Osaka University Hospital), Akio Matsubara, Noriaki Yorioka (Hiroshima University Hospital), Kanzuhiko Tsuruya (Kyushu University Hospital), and Kimio Tomita (Kumamoto University Hospital). The authors thank Kenji Uehara (Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Japan) for his cooperation in medical writing of the manuscript, and both Kenji Uehara and Hisashi Naga-moto (Medical Affairs, Otsuka Pharmaceutical Co., Ltd., Japan) for quality control of the manuscript. This work was financially supported by Otsuka Pharmaceutical Co., Ltd., Japan, and Otsuka Pharmaceutical Development & Commercialization, Inc., USA, in terms of the study design; collection, analysis, and interpretation of data; writing of the report; and manuscript preparation.

Author contributions SH, SM, HK, and TO contributed to the concept and design of the post hoc analysis; YS contributed to the acquisition and analysis of the data; and SH, SM, HK, TO, YS, KN, and TI contributed to the interpretation of the data, critically revised the manuscript, approved the final manuscript, and agreed to be accountable for all aspects of the manuscript.

Compliance with ethical standards

Conflict of interest S.H. has received advisory board fees, lecture fees, and grant support as an endowned department from Otsuka Pharmaceutical Co., Ltd. and advisory board fees from Sanofi. S.M. has received lecture fees from Otsuka Pharmaceutical Co., Ltd. and belongs to an endowned department sponsored by Otsuka Pharmaceutical Co., Ltd. H.K. belongs to an endowned department sponsored by Otsuka Pharmaceutical Co., Ltd. T.O., Y.S., and T.I. are full-time employees of Otsuka Pharmaceutical Co., Ltd. K.N. is a former employee of Otsuka Pharmaceutical Co., Ltd.

Research involving human participants TEMPO 3:4 was conducted in accordance with the ethical principles originating in the Declaration of Helsinki and in compliance with good clinical practice guidelines. The protocol was approved by the institutional review board (IRB) at each trial site. The first patient was enrolled in Niigata University Medical and Dental Hospital (IRB approval number: CH19-002a).

Informed consent Written informed consent was obtained from all participating patients.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will
References

1. Grantham JJ, Torres VE, Chapman AB, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122–30.
2. Chebib FT, Torres VE. Autosomal dominant polycystic kidney disease: core curriculum 2016. Am J Kidney Dis. 2016;67:792–810.
3. Grantham JJ, Chapman AB, Torres VE. Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol. 2006;1:148–57.
4. Chapman AB, Bost JE, Torres VE, et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2012;7:479–86.
5. Gattone VH 2nd, Wang X, Harris PC, et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9:1323–6.
6. Torres VE, Wang X, Qian Q, et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10:363–4.
7. Wang X, Gattone V 2nd, Harris PC, et al. Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat. J Am Soc Nephrol. 2005;16:846–51.
8. Wang X, Wu Y, Ward CJ, et al. Vasopressin directly regulates cyst growth in polycystic kidney disease. J Am Soc Nephrol. 2008;19:102–8.
9. Aihara M, Fujiki H, Mizuguchi H, et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther. 2014;349:258–67.
10. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407–18.
11. Muto S, Kawano H, Higashihara E, et al. The effect of tolvaptan on autosomal dominant polycystic kidney disease patients: a subgroup analysis of the Japanese patient subset from TEMPO 3:4 trial. Clin Exp Nephrol. 2015;19:867–77.
12. Irazabal MV, Rangel LJ, Bergstrahl EJ, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160–72.
13. Torres VE, Meijer E, Bae KT, et al. Rationale and design of the TEMPO (tolvaptan efficacy and safety in management of autosomal dominant polycystic kidney disease and its outcomes) 3:4 study. Am J Kidney Dis. 2011;57:692–9.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
15. Horio M, Imai E, Yasuda Y, et al. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32–8.
16. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
17. The International Society of Nephrology. Summary of recommendation statements. Kidney Int Suppl. 2013;3:5–14.
18. Reif GA, Yamaguchi T, Nivens E, et al. Tolvaptan inhibits ERK-dependent cell proliferation, Cl− secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin. Am J Physiol Renal Physiol. 2011;301:F1005–13.
19. Higashihara E, Nutahara K, Okegawa T, et al. Kidney volume and function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2014;18:157–65.
20. Lanke S, Shoaf SE. Population pharmacokinetic analyses and model validation of tolvaptan in subjects with autosomal dominant polycystic kidney disease. J Clin Pharmacol. 2019;59:763–70.
21. Devuyst O, Chapman AB, Gansevoort RT, et al. Urine osmolality, response to tolvaptan, and outcome in autosomal dominant polycystic kidney disease: results from the TEMPO 3:4 trial. J Am Soc Nephrol. 2017;28:1592–602.
22. Boertien WE, Meijer E, Li J, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis. 2013;61:420–9.
23. Gansevoort RT, van Gastel MDA, Chapman AB, et al. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019;96:159–69.
24. Perinpan M, Ware EB, Smith JA, et al. Key influence of sex on urine volume and osmolality. Biol Sex Differ. 2016;7:12.
25. Irazabal MV, Blais JD, Perrone RD, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the TEMPO 3:4 clinical trial. Kidney Int Rep. 2016;1:213–20.
26. Irazabal MV, Abebe KZ, Bae KT, et al. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial. Nephrol Dial Transplant. 2017;32:1857–65.
27. Bardoux P, Bruneval P, Heudes D, et al. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant. 2003;18:1755–63.
28. Bardoux P, Martin H, Ahloulay M, et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci U S A. 1999;96:10397–402.
29. Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci. 2009;116:257–63.
30. Meijer E, Bakker SJ, de Jong PE, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation. 2009;88:561–7.
31. Villela-Torres ML, Higareda-Mendoza AE, Gómez-García A, et al. Copeptin plasma levels are associated with decline of renal function in patients with type 2 diabetes mellitus. Arch Med Res. 2018;49:36–43.
32. Perico N, Zoja C, Corna D, et al. V1/V2 vasopressin receptor antagonism potentiates the renoprotection of renin-angiotensin system inhibition in rats with renal mass reduction. Kidney Int. 2009;76:960–7.
33. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in late-stage autosomal dominant polycystic kidney disease. N Engl J Med. 2017;377:1930–42.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.